COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,010 Articles (22,627 medRxiv, 8,383 bioRxiv)

Most recent first Previous |  Page 2395: Articles 23941-23950  | Next

Persistent heterogeneity not short-term overdispersion determines herd immunity to COVID-19
Tkachenko, A. V., Maslov, S., Elbanna, A., Wong, G., Weiner, Z., Goldenfeld, N.
10.1101/2020.07.26.20162420 — Posted: 2020-07-29 Discussion: Onsite
Mathematical Modelling the Impact Evaluation ofLockdown on Infection Dynamics of COVID-19 inItaly.
Yergesh, D., Kadyrov, S., Saydaliev, H., Orynbassar, A.
10.1101/2020.07.27.20162537 — Posted: 2020-07-29
Non-COVID-19 deaths in the United States during the imposition of sheltering-in-place
Catalano, R., Casey, J. A., Gemmill, A., Bruckner, T.-A.
10.1101/2020.07.26.20162396 — Posted: 2020-07-29
Understanding the patterns of repeated testing for COVID-19: Association with patient characteristics and outcomes
Salerno, S., Zhao, Z., Prabhu Sankar, S., Salvatore, M., Gu, T., Fritsche, L. G., Lee, S., Lisabeth, L. D., Valley, T. S., Mukherjee, B.
10.1101/2020.07.26.20162453 — Posted: 2020-07-29
SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals
Hansen, C. B., Jarlhelt, I., Perez-Alos, L., Hummelshoj Landsy, L., Loftager, M., Rosbjerg, A., Helgstrand, C., Bjelke, J. R., Egebjerg, T., Jardine, J. G., Svaerke Jorgensen, C., Iversen, K., Bayarri-Olmos, R., Garred, P., Skjoedt, M.-O.
10.1101/2020.07.27.20162321 — Posted: 2020-07-29 Discussion: Onsite
Efficacy and tolerability of bevacizumab in patients with severe Covid -19
Pang, J., Xu, F., Aondio, G., Li, Y., Fumagalli, A., Lu, M., Valmadre, G., Wei, J., Bian, Y., Canesi, M., Damiani, G., Zhang, Y., Yu, D., Chen, J., Ji, X., Sui, W., Wang, B., Wu, S., Kovacs, A., Revera, M., Wang, H., Zhang, Y., Chen, Y., Cao, Y.
10.1101/2020.07.26.20159756 — Posted: 2020-07-29
Magnetic bead-based ELISA allow inexpensive, rapid and quantitative detection of human antibodies against SARS-CoV-2
Huergo, L. F., Conzentino, M. S., Gerhardt, E. C. M., Santos, A. R. S., Pedrosa, F. d. O., Souza, E. M., Nogueira, M. B., Forchhammer, K., Rego, F. G. M., Raboni, S. M., Reis, R. A.
10.1101/2020.07.26.20162255 — Posted: 2020-07-29
A rapid and sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry
Singh, P., Chakraborty, R., Marwal, R., V S, R., Bhaskar, A. K., Vashisht, H., Dhar, M. S., Pradhan, S., Ranjan, G., Imran, M., Raj, A., Sharma, U., Singh, P., Lall, H., Dutta, M., Garg, P., Ray, A., Dash, D., Sivasubbu, S., Gogia, H., Madan, P., Kabra, S., Singh, S. K., Agrawal, A., Rakhit, P., Kumar, P., Sengupta, S.
10.1101/2020.07.27.20161836 — Posted: 2020-07-29
A machine learning explanation of the pathogen-immune relationship of SARS-CoV-2 and machine learning models of prognostic biomarkers to predict asymptomatic or symptomatic infections
Luellen, E.
10.1101/2020.07.27.20162867 — Posted: 2020-07-29 Discussion: Onsite
The German Corona Consensus Dataset (GECCO): A standardized dataset for COVID-19 research
Sass, J., Bartschke, A., Lehne, M., Essenwanger, A., Rinaldi, E., Rudolph, S., Heitmann, K. U., Vehreschild, J. J., von Kalle, C., Thun, S.
10.1101/2020.07.27.20162636 — Posted: 2020-07-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).